Raffaele Colombo: Evoke-01 study of sacituzumab govitecan (SG) did not meet its primary overall survival goal in patients with NSCLC

Raffaele Colombo, Principal Scientist at Zymeworks, shared on X:

“Evoke-01 study of sacituzumab govitecan (SG) did not meet its primary overall survival goal in patients with NSCLC

‘A numerical improvement in OS favoring SG was observed’

‘A more than 3-month difference in OS favoring SG was observed in a sub-group'”

Read further.
Source: Raffaele Colombo/X